Manhattan Scientifics Inc represents values of innovation, technological advancement, and financial growth. With a strong corporate philosophy centered on groundbreaking research and development, the company strives to provide cutting-edge solutions in the field of nanotechnology. Through its commitment to excellence and staying at the forefront of scientific progress, Manhattan Scientifics Inc aims to deliver innovative products and services that can impact various industries. This forward-thinking approach has earned the company a reputation for driving change and bringing transformative technologies to market. By focusing on these core values, Manhattan Scientifics Inc continues to pave the way for advancements in nanotechnology and contribute to the future of scientific exploration.

Manhattan Scientifics Inc is primarily present in the United States of America.

Manhattan Scientifics Inc has achieved significant milestones throughout its history. One notable accomplishment is the development of the NanoMRX platform, a cutting-edge technology for detecting cancer. Additionally, the company has successfully commercialized its revolutionary Magnetic Field Applicator (MFA) for the treatment of cancerous tumors. Manhattan Scientifics Inc has also made substantial progress in the field of nanotechnology, with breakthrough advancements in high-performance metals and alloys. These achievements demonstrate the company's commitment to innovation and its continual pursuit of advancements in the fields of medicine and materials science.

Manhattan Scientifics Inc. is a technology-focused company established in 1992. With headquarters in New Mexico, the company has centered its efforts around the development and commercialization of innovative technologies. Leveraging its expertise in nano-materials and nano-composites, Manhattan Scientifics has pioneered advancements in areas such as cancer detection and treatment, imaging diagnostics, and homeland security. Through strategic partnerships and collaborations, the company has successfully introduced groundbreaking products and solutions to the market. As an industry leader, Manhattan Scientifics continues to drive innovation and deliver cutting-edge technologies that address critical global challenges, positioning itself for future growth and success.

The main competitors of Manhattan Scientifics Inc in the market include companies such as General Electric Company (GE), Siemens AG, and Philips Electronics N.V. These industry leaders also operate in the healthcare and nanotechnology sectors, competing with Manhattan Scientifics Inc in areas such as medical imaging, diagnostics, and innovative material applications.

Manhattan Scientifics Inc is primarily active in the industries of advanced materials and nanotechnology.

The business model of Manhattan Scientifics Inc is centered around the commercialization of disruptive technologies in the areas of medicine and nanotechnology. The company aims to bring innovative solutions to market that can significantly improve patient outcomes and advance the field of healthcare. With a focus on developing and licensing proprietary technologies, Manhattan Scientifics Inc works closely with strategic partners to accelerate the adoption and commercial success of their products. By leveraging their expertise and intellectual property portfolio, the company strives to create value for its shareholders and contribute to the advancement of scientific research and development.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Manhattan Scientifics.

KUV:tä ei voida tällä hetkellä laskea Manhattan Scientifics osalta.

AlleAktien Laatuscore Manhattan Scientifics on 5/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Manhattan Scientifics.

Voitto ei voida tällä hetkellä laskea yritykselle Manhattan Scientifics.

Manhattan Scientifics Inc is an American company that was founded in 1994. The company is based in New York and is involved in the development of innovative technologies in various fields. Its main focus is on nanotechnology, where it develops materials and systems that operate at the nano scale using nanoparticles and nanofibers. It also operates in the biotechnology sector, focusing on researching cancer and other serious diseases. Additionally, it develops technologies in the field of renewable energy, such as new battery technologies. Manhattan Scientifics aims to establish its technologies in the market through collaborations and spin-off companies. Its most well-known products include lightweight and durable materials used in aircraft and automotive industries, as well as a platform for precise manufacturing of medical devices. Overall, Manhattan Scientifics specializes in the development and marketing of technologies and products in various fields, aiming to increase their dissemination and market success through partnerships and new ventures.

Manhattan Scientifics maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Manhattan Scientifics:lle tai yhtiö ei maksa osinkoa.

Manhattan Scientifics:n ISIN on US5631221000.

Manhattan Scientifics:n WKN on 911936.

Manhattan Scientifics:n tunnus on MHTX.

Viimeisen 12 kuukauden aikana Manhattan Scientifics maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Manhattan Scientifics maksanee ennusteiden mukaan 0 USD osingon.

Manhattan Scientifics:n tämänhetkinen osinkotuotto on .

Manhattan Scientifics maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Manhattan Scientifics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Manhattan Scientifics kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Manhattan Scientifics osingon 29.6.2025, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 29.6.2025.

Viimeisin osinko maksettiin 29.6.2025.

Vuonna 2024 Manhattan Scientifics maksoi 0 USD osinkoina.

Manhattan Scientifics:n osingot maksetaan USDssa.